These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37058419)

  • 1. Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI.
    Redondo S; García-Cadenas I; Vila A; Esquirol A; Portos JM; Novelli S; Saavedra S; Moreno C; Garrido A; Arguello-Tomas M; Oñate G; López-Pardo J; Caballero AC; Miqueleiz S; Briones J; Sierra J; Sancho G; Martino R
    Eur J Haematol; 2023 Jul; 111(1):146-153. PubMed ID: 37058419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
    Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Labopin M; Schroeder T; Swoboda R; Maertens J; Bourhis JH; Grillo G; Salmenniemi U; Hilgendorf I; Kröger N; Poiré X; Cornelissen JJ; Arat M; Savani B; Spyridonidis A; Nagler A; Mohty M
    Am J Hematol; 2023 Apr; 98(4):580-587. PubMed ID: 36626592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia.
    Holter-Chakrabarty JL; Pierson N; Zhang MJ; Zhu X; Akpek G; Aljurf MD; Artz AS; Baron F; Bredeson CN; Dvorak CC; Epstein RB; Lazarus HM; Olsson RF; Selby GB; Williams KM; Cooke KR; Pasquini MC; McCarthy PL
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1251-7. PubMed ID: 25840335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Socié G; Aljurf M; Salmenniemi U; Labussière-Wallet H; Srour M; Kröger N; Zahrani MA; Lioure B; Reményi P; Arat M; Bourhis JH; Helbig G; Tbakhi A; Forcade E; Huynh A; Brissot E; Spirydonidis A; Savani BN; Peric Z; Nagler A; Mohty M
    Bone Marrow Transplant; 2023 May; 58(5):506-513. PubMed ID: 36725978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
    Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Modi D; Kondrat K; Kim S; Deol A; Ayash L; Ratanatharathorn V; Uberti JP
    Transplant Cell Ther; 2021 Sep; 27(9):760-767. PubMed ID: 34174469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.
    Czyz A; Labopin M; Giebel S; Socié G; Apperley J; Volin L; Reményi P; Yakoub-Agha I; Orchard K; Michallet M; Stuhler G; Chaganti S; Murray M; Aljurf M; Bloor A; Passweg J; Finke J; Mohty M; Nagler A
    Am J Hematol; 2018 Jun; 93(6):778-785. PubMed ID: 29574915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission.
    Stein AS; Al Malki MM; Yang D; Palmer JM; Tsai NC; Aldoss I; Ali H; Aribi A; Artz A; Dandapani S; Farol L; Hui S; Liu A; Nakamura R; Pullarkat V; Radany E; Rosenthal J; Salhotra A; Sanchez JF; Spielberger R; Marcucci G; Forman SJ; Wong J
    Transplant Cell Ther; 2022 Jul; 28(7):368.e1-368.e7. PubMed ID: 35398328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.
    Kanakry CG; O'Donnell PV; Furlong T; de Lima MJ; Wei W; Medeot M; Mielcarek M; Champlin RE; Jones RJ; Thall PF; Andersson BS; Luznik L
    J Clin Oncol; 2014 Nov; 32(31):3497-505. PubMed ID: 25267759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Jurdi NE; Hoover A; O'Leary D; Cao Q; Gupta A; Ebens C; Maakaron JE; Betts BC; Rashidi A; Juckett MB; Lund T; Bachanova V; MacMillan ML; Miller JS; Orchard PJ; Wagner JE; Vercellotti G; Weisdorf DJ; Dusenbery K; Terezakis S; Holtan SG
    Transplant Cell Ther; 2023 Sep; 29(9):576.e1-576.e5. PubMed ID: 37311510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation.
    Solomon SR; Bachier-Rodriguez L; Bashey A; Zhang X; Jackson KC; Holland HK; Morris LE; Solh MM
    Transplant Cell Ther; 2024 Sep; 30(9):903.e1-903.e9. PubMed ID: 38879167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia.
    Dholaria B; Labopin M; Angelucci E; Tischer J; Arat M; Ciceri F; Gülbas Z; Ozdogu H; Sica S; Diez-Martin JL; Koc Y; Pavlu J; Socié G; Giebel S; Savani BN; Nagler A; Mohty M
    Transplant Cell Ther; 2021 Feb; 27(2):171.e1-171.e8. PubMed ID: 33830029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.